title: Reperfusion injury and its pharmacologic modification.
abstract: Reperfusion injury includes a spectrum of events, such as reperfusion arrhythmias, vascular damage and no-reflow, and myocardial functional stunning. The concept of reperfusion injury remains controversial with many proposed mechanisms when applied to humans, whereas in animal models, there are two main proposed mechanisms: calcium over-load and formation of oxygen free radicals. To prove that reperfusion injury is specifically caused by reperfusion would require evidence that an intervention given at the time of reperfusion can diminish or abolish the injury as in the case of arrhythmias, which are thought to be mediated by excess recycling of cytosolic calcium with delayed afterdepolarizations and ventricular automaticity. In the case of myocardial stunning, the phenomenon may be mediated, at least in part, by a burst of free radicals formed within the first minute of reperfusion and improved by free radical scavengers given at the time of reperfusion. The alternate hypothesis is that cytosolic calcium overload damages mechanisms for normal intracellular calcium regulation so that the stunned myocardium responds to agents that are thought to increase intracellular cytosolic calcium, such as beta-receptor agonists. A further component of reperfusion injury, under active investigation, is microvascular damage with alterations at the level of platelets, leukocytes, and endothelial integrity. From the therapeutic point of view, the divergent results of experimental interventions and the possibility that the abrupt onset of reperfusion in animals differs from the situation in humans with thrombolysis means that the best way currently available to limit reperfusion injury is by minimizing the ischemic period by early reperfusion and by optimizing the metabolic status of the ischemic myocardium at the end of the ischemic period.
authors.affiliation: Heart Research Unit, University of Cape Town, Medical School, South Africa.
authors.forename: L H
authors.initials: LH
authors.lastname: Opie
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004338:Drug Combinations; D005343:Fibrinolytic Agents / Q000494:pharmacology; D005609:Free Radicals; D006321:Heart / Q000503:physiopathology; D006801:Humans; D015428:Myocardial Reperfusion Injury / Q000150:complications / Q000209:etiology / Q000517:prevention & control*; D009206:Myocardium / Q000473:pathology; D010100:Oxygen / Q000378:metabolism; D014652:Vascular Diseases / Q000209:etiology
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D004338:Drug Combinations; D005343:Fibrinolytic Agents; D005609:Free Radicals; D010100:Oxygen; D002118:Calcium